It was reported that the vaccine, manufactured in partnership with Medicago headquartered in Quebec City, Quebec, Canada, and British pharmaceutical company GlaxoSmithKline (GSK) showed high efficacy against infection during Phase III clinical trials.
“Incidence rate 71 percent”
The overall effectiveness rate of the vaccine against all the virus variants studied was 71 percent, said the statement given by the company.
The statement, which said necessary applications would be made to Canada’s Ministry of Health, did not include details about the vaccine’s plant ingredients.
“First Plant Based Vaccine”
Medicago spokesman Brian Ward told CBC that if the ministry grants a license, the vaccine would be the first COVID-19 vaccine to use virus-like particle technology and the first plant-based vaccine approved for human use.
“It will be a first for the world, not just Quebec and Canada,” Ward said. said.
Plant-based vaccines use plant-derived virus-like particles that are similar to the coronavirus but do not contain its genetic material.
According to the statement, the vaccine was supplemented with a booster adjuvant to help boost the immune response.
Full results of the Phase 3 trial will soon be published in a peer-reviewed scientific publication, Medicago said in a statement. (aa)
